Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 81 entries
Sorted by: Best Match Show Resources per page
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Frontiers in pharmacology

Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D.
PMID: 27242528
Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016.

In the human genome more than 400 genes encode ion channels, which are transmembrane proteins mediating ion fluxes across membranes. Being expressed in all cell types, they are involved in almost all physiological processes, including sense perception, neurotransmission, muscle...

Cite
Imbrici P, Liantonio A, Camerino GM, et al. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol. 2016;7:121doi: 10.3389/fphar.2016.00121.
Imbrici, P., Liantonio, A., Camerino, G. M., De Bellis, M., Camerino, C., Mele, A., Giustino, A., Pierno, S., De Luca, A., Tricarico, D., Desaphy, J. F., & Conte, D. (2016). Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Frontiers in pharmacology, 7121. https://doi.org/10.3389/fphar.2016.00121
Imbrici, Paola, et al. "Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery." Frontiers in pharmacology vol. 7 (2016): 121. doi: https://doi.org/10.3389/fphar.2016.00121
Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016. PMID: 27242528; PMCID: PMC4861771.
Copy Download .nbib Format: NLM
Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers.

Clinical pharmacology : advances and applications

Kawabata M, Yokoyama Y, Sasaki T, Tao S, Ihara K, Shirai Y, Sasano T, Goya M, Furukawa T, Isobe M, Hirao K.
PMID: 25733934
Clin Pharmacol. 2015 Feb 16;7:29-36. doi: 10.2147/CPAA.S77021. eCollection 2015.

PURPOSE: Drug-induced bradycardia is common during antiarrhythmic therapy; the major culprits are beta-blockers. However, whether other antiarrhythmic drugs are also a significant cause of this, alone or in combination with beta-blockers, is not well known.METHODS: We retrospectively investigated the...

Cite
Kawabata M, Yokoyama Y, Sasaki T, et al. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015;7:29-36doi: 10.2147/CPAA.S77021.
Kawabata, M., Yokoyama, Y., Sasaki, T., Tao, S., Ihara, K., Shirai, Y., Sasano, T., Goya, M., Furukawa, T., Isobe, M., & Hirao, K. (2015). Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clinical pharmacology : advances and applications, 729-36. https://doi.org/10.2147/CPAA.S77021
Kawabata, Mihoko, et al. "Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers." Clinical pharmacology : advances and applications vol. 7 (2015): 29-36. doi: https://doi.org/10.2147/CPAA.S77021
Kawabata M, Yokoyama Y, Sasaki T, Tao S, Ihara K, Shirai Y, Sasano T, Goya M, Furukawa T, Isobe M, Hirao K. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015 Feb 16;7:29-36. doi: 10.2147/CPAA.S77021. eCollection 2015. PMID: 25733934; PMCID: PMC4337503.
Copy Download .nbib Format: NLM
Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia.

Current treatment options in neurology

Strupp M, Dieterich M, Brandt T, Feil K.
PMID: 27306762
Curr Treat Options Neurol. 2016 Jul;18(7):34. doi: 10.1007/s11940-016-0417-2.

OPINION STATEMENT: Neurovascular compression syndromes are characterized by recurrent attacks of neurological symptoms and clinical signs depending on the cranial nerve affected. It is assumed that pulsatile compression of the nerve is caused mainly by an artery. The result...

Cite
Strupp M, Dieterich M, Brandt T, et al. Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia. Curr Treat Options Neurol. 2016;18(7):34doi: 10.1007/s11940-016-0417-2.
Strupp, M., Dieterich, M., Brandt, T., & Feil, K. (2016). Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia. Current treatment options in neurology, 18(7), 34. https://doi.org/10.1007/s11940-016-0417-2
Strupp, Michael, et al. "Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia." Current treatment options in neurology vol. 18,7 (2016): 34. doi: https://doi.org/10.1007/s11940-016-0417-2
Strupp M, Dieterich M, Brandt T, Feil K. Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia. Curr Treat Options Neurol. 2016 Jul;18(7):34. doi: 10.1007/s11940-016-0417-2. PMID: 27306762.
Copy Download .nbib Format: NLM
How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?.

Journal of atrial fibrillation

Burashnikov A, Antzelevitch C.
PMID: 21057583
J Atr Fibrillation. 2008;1(2):98-107. doi: 10.4022/jafib.v1i1.400.

Current pharmacologic strategies for the management of Atrial fibrillation (AF) include use of 1) sodium channel blockers, which are contraindicated in patients with coronary artery or structural heart disease because of their potent effect to slow conduction in the...

Cite
Burashnikov A, Antzelevitch C. How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?. J Atr Fibrillation. 2008;1(2):98-107doi: 10.4022/jafib.v1i1.400.
Burashnikov, A., & Antzelevitch, C. (2008). How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?. Journal of atrial fibrillation, 1(2), 98-107. https://doi.org/10.4022/jafib.v1i1.400
Burashnikov, Alexander, and Antzelevitch, Charles. "How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?." Journal of atrial fibrillation vol. 1,2 (2008): 98-107. doi: https://doi.org/10.4022/jafib.v1i1.400
Burashnikov A, Antzelevitch C. How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?. J Atr Fibrillation. 2008;1(2):98-107. doi: 10.4022/jafib.v1i1.400. PMID: 21057583; PMCID: PMC2970929.
Copy Download .nbib Format: NLM
Identification of deep-sea-sediment bacteria which produce tetrodotoxin.

Applied and environmental microbiology

Do HK, Kogure K, Simidu U.
PMID: 16348162
Appl Environ Microbiol. 1990 Apr;56(4):1162-3. doi: 10.1128/aem.56.4.1162-1163.1990.

Forty-nine bacterial strains were isolated from deep-sea sediments. Among them, 22 strains were shown by the tissue culture assay method to produce sodium channel blockers. For some strains, high-performance liquid chromatography analysis confirmed that the blocker was tetrodotoxin. Tetrodotoxin-producing...

Cite
Do HK, Kogure K, Simidu U. Identification of deep-sea-sediment bacteria which produce tetrodotoxin. Appl Environ Microbiol. 1990;56(4):1162-3doi: 10.1128/aem.56.4.1162-1163.1990.
Do, H. K., Kogure, K., & Simidu, U. (1990). Identification of deep-sea-sediment bacteria which produce tetrodotoxin. Applied and environmental microbiology, 56(4), 1162-3. https://doi.org/10.1128/aem.56.4.1162-1163.1990
Do, H K, et al. "Identification of deep-sea-sediment bacteria which produce tetrodotoxin." Applied and environmental microbiology vol. 56,4 (1990): 1162-3. doi: https://doi.org/10.1128/aem.56.4.1162-1163.1990
Do HK, Kogure K, Simidu U. Identification of deep-sea-sediment bacteria which produce tetrodotoxin. Appl Environ Microbiol. 1990 Apr;56(4):1162-3. doi: 10.1128/aem.56.4.1162-1163.1990. PMID: 16348162; PMCID: PMC184361.
Copy Download .nbib Format: NLM
Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?.

Neurology and therapy

Lawthom C, Peltola J, McMurray R, Dodd E, Villanueva V.
PMID: 30251237
Neurol Ther. 2018 Dec;7(2):195-206. doi: 10.1007/s40120-018-0111-2. Epub 2018 Sep 24.

Carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL) belong to the dibenzazepine family of antiepileptic drugs and are all thought to primarily act as sodium channel blockers (SCBs). However, ESL is structurally distinct from CBZ and OXC, resulting in...

Cite
Lawthom C, Peltola J, McMurray R, et al. Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?. Neurol Ther. 2018;7(2):195-206doi: 10.1007/s40120-018-0111-2.
Lawthom, C., Peltola, J., McMurray, R., Dodd, E., & Villanueva, V. (2018). Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?. Neurology and therapy, 7(2), 195-206. https://doi.org/10.1007/s40120-018-0111-2
Lawthom, Charlotte, et al. "Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?." Neurology and therapy vol. 7,2 (2018): 195-206. doi: https://doi.org/10.1007/s40120-018-0111-2
Lawthom C, Peltola J, McMurray R, Dodd E, Villanueva V. Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?. Neurol Ther. 2018 Dec;7(2):195-206. doi: 10.1007/s40120-018-0111-2. Epub 2018 Sep 24. PMID: 30251237; PMCID: PMC6283801.
Copy Download .nbib Format: NLM
A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease.

Frontiers in pharmacology

Lee SY, Song MY, Kim D, Park C, Park DK, Kim DG, Yoo JS, Kim YH.
PMID: 32063857
Front Pharmacol. 2020 Jan 29;10:1653. doi: 10.3389/fphar.2019.01653. eCollection 2019.

Numerous clinical trials of drug candidates for Alzheimer's disease (AD) have failed, and computational drug repositioning approaches using omics data have been proposed as effective alternative approaches to the discovery of drug candidates. However, little multi-omics data is available...

Cite
Lee SY, Song MY, Kim D, et al. A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease. Front Pharmacol. 2020;10:1653doi: 10.3389/fphar.2019.01653.
Lee, S. Y., Song, M. Y., Kim, D., Park, C., Park, D. K., Kim, D. G., Yoo, J. S., & Kim, Y. H. (2019). A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease. Frontiers in pharmacology, 101653. https://doi.org/10.3389/fphar.2019.01653
Lee, Soo Youn, et al. "A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease." Frontiers in pharmacology vol. 10 (2019): 1653. doi: https://doi.org/10.3389/fphar.2019.01653
Lee SY, Song MY, Kim D, Park C, Park DK, Kim DG, Yoo JS, Kim YH. A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease. Front Pharmacol. 2020 Jan 29;10:1653. doi: 10.3389/fphar.2019.01653. eCollection 2019. PMID: 32063857; PMCID: PMC7000455.
Copy Download .nbib Format: NLM
Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice.

Synapse (New York, N.Y.)

Yoshizawa K, Arai N, Suzuki Y, Nakamura T, Takeuchi K, Sakamoto R, Masuda R.
PMID: 29993143
Synapse. 2018 Jul 11; doi: 10.1002/syn.22056. Epub 2018 Jul 11.

An important role of voltage-gated sodium channels (VGSCs) in many different pain states has been established in animal models and humans wherein sodium channel blockers partially ameliorate pain. However, behavioral tests for screening analgesics that exhibit pharmacologic action by...

Cite
Yoshizawa K, Arai N, Suzuki Y, et al. Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice. Synapse. 2018;doi: 10.1002/syn.22056.
Yoshizawa, K., Arai, N., Suzuki, Y., Nakamura, T., Takeuchi, K., Sakamoto, R., & Masuda, R. (2018). Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice. Synapse (New York, N.Y.), . https://doi.org/10.1002/syn.22056
Yoshizawa, Kazumi, et al. "Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice." Synapse (New York, N.Y.) vol. (2018). doi: https://doi.org/10.1002/syn.22056
Yoshizawa K, Arai N, Suzuki Y, Nakamura T, Takeuchi K, Sakamoto R, Masuda R. Evaluation of the antinociceptive activities of several sodium channel blockers using veratrine test in mice. Synapse. 2018 Jul 11; doi: 10.1002/syn.22056. Epub 2018 Jul 11. PMID: 29993143.
Copy Download .nbib Format: NLM
Predictive validity of pharmacologic interventions in animal models of neuropathic pain.

Scandinavian journal of pain

Honoré PH, Basnet A, Kristensen P, Andersen LM, Neustrup S, Møllgaard P, Eljaja L, Bjerrum OJ.
PMID: 29913756
Scand J Pain. 2011 Oct 01;2(4):178-184. doi: 10.1016/j.sjpain.2011.06.002.

Introduction The pathophysiologic and neurochemical characteristics of neuropathic pain must be considered in the search for new treatment targets. Breakthroughs in the understanding of the structural and biochemical changes in neuropathy have opened up possibilities to explore new treatment...

Cite
Honoré PH, Basnet A, Kristensen P, et al. Predictive validity of pharmacologic interventions in animal models of neuropathic pain. Scand J Pain. 2011;2(4):178-184doi: 10.1016/j.sjpain.2011.06.002.
Honoré, P. H., Basnet, A., Kristensen, P., Andersen, L. M., Neustrup, S., Møllgaard, P., Eljaja, L., & Bjerrum, O. J. (2011). Predictive validity of pharmacologic interventions in animal models of neuropathic pain. Scandinavian journal of pain, 2(4), 178-184. https://doi.org/10.1016/j.sjpain.2011.06.002
Honoré, Per Hartvig, et al. "Predictive validity of pharmacologic interventions in animal models of neuropathic pain." Scandinavian journal of pain vol. 2,4 (2011): 178-184. doi: https://doi.org/10.1016/j.sjpain.2011.06.002
Honoré PH, Basnet A, Kristensen P, Andersen LM, Neustrup S, Møllgaard P, Eljaja L, Bjerrum OJ. Predictive validity of pharmacologic interventions in animal models of neuropathic pain. Scand J Pain. 2011 Oct 01;2(4):178-184. doi: 10.1016/j.sjpain.2011.06.002. PMID: 29913756.
Copy Download .nbib Format: NLM
Phenotypic and genetic spectrum in Chinese children with SCN8A-related disorders.

Seizure

Hu C, Luo T, Wang Y.
PMID: 34979445
Seizure. 2021 Dec 25;95:38-49. doi: 10.1016/j.seizure.2021.12.011. Epub 2021 Dec 25.

BACKGROUND: Pathogenic variants in SCN8A have been demonstrated with a wide spectrum of epilepsy phenotypes, ranging from benign infantile epilepsy (BIE), to early onset developmental and epileptic encephalopathy (DEE) with moderate to severe developmental delay. In order to provide...

Cite
Hu C, Luo T, Wang Y. Phenotypic and genetic spectrum in Chinese children with SCN8A-related disorders. Seizure. 2021;95:38-49doi: 10.1016/j.seizure.2021.12.011.
Hu, C., Luo, T., & Wang, Y. (2021). Phenotypic and genetic spectrum in Chinese children with SCN8A-related disorders. Seizure, 9538-49. https://doi.org/10.1016/j.seizure.2021.12.011
Hu, Chunhui, et al. "Phenotypic and genetic spectrum in Chinese children with SCN8A-related disorders." Seizure vol. 95 (2021): 38-49. doi: https://doi.org/10.1016/j.seizure.2021.12.011
Hu C, Luo T, Wang Y. Phenotypic and genetic spectrum in Chinese children with SCN8A-related disorders. Seizure. 2021 Dec 25;95:38-49. doi: 10.1016/j.seizure.2021.12.011. Epub 2021 Dec 25. PMID: 34979445.
Copy Download .nbib Format: NLM
Neuropharmacological basis for multimodal analgesia in chronic pain.

Postgraduate medicine

Patel R, Dickenson AH.
PMID: 34636261
Postgrad Med. 2021 Oct 28;1-15. doi: 10.1080/00325481.2021.1985351. Epub 2021 Oct 28.

Managing chronic pain remains a major unmet clinical challenge. Patients can be treated with a range of interventions, but pharmacotherapy is the most common. These include opioids, antidepressants, calcium channel modulators, sodium channel blockers, and nonsteroidal anti-inflammatory drugs. Many...

Cite
Patel R, Dickenson AH. Neuropharmacological basis for multimodal analgesia in chronic pain. Postgrad Med. 2021;1-15doi: 10.1080/00325481.2021.1985351.
Patel, R., & Dickenson, A. H. (2021). Neuropharmacological basis for multimodal analgesia in chronic pain. Postgraduate medicine, 1-15. https://doi.org/10.1080/00325481.2021.1985351
Patel, Ryan, and Dickenson, Anthony H. "Neuropharmacological basis for multimodal analgesia in chronic pain." Postgraduate medicine vol. (2021): 1-15. doi: https://doi.org/10.1080/00325481.2021.1985351
Patel R, Dickenson AH. Neuropharmacological basis for multimodal analgesia in chronic pain. Postgrad Med. 2021 Oct 28;1-15. doi: 10.1080/00325481.2021.1985351. Epub 2021 Oct 28. PMID: 34636261.
Copy Download .nbib Format: NLM
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).

CNS drugs

Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, De Maria G, Didato G, Falcicchio G, Fanella M, Ferlazzo E, Fisco G, Gangitano M, Giallonardo AT, Giorgi FS, La Neve A, Mecarelli O, Montalenti E, Piazza F, Pulitano P, Quarato PP, Ranzato F, Rosati E, Tassi L, Di Bonaventura C.
PMID: 34476770
CNS Drugs. 2021 Dec;35(12):1289-1301. doi: 10.1007/s40263-021-00856-3. Epub 2021 Sep 02.

BACKGROUND: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile.OBJECTIVE: This multicentre study assessed the effectiveness and...

Cite
Lattanzi S, Canafoglia L, Canevini MP, et al. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021;35(12):1289-1301doi: 10.1007/s40263-021-00856-3.
Lattanzi, S., Canafoglia, L., Canevini, M. P., Casciato, S., Chiesa, V., Dainese, F., De Maria, G., Didato, G., Falcicchio, G., Fanella, M., Ferlazzo, E., Fisco, G., Gangitano, M., Giallonardo, A. T., Giorgi, F. S., La Neve, A., Mecarelli, O., Montalenti, E., Piazza, F., Pulitano, P., Quarato, P. P., Ranzato, F., Rosati, E., Tassi, L., Di Bonaventura, C. (2021). Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). CNS drugs, 35(12), 1289-1301. https://doi.org/10.1007/s40263-021-00856-3
Lattanzi, Simona, et al. "Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)." CNS drugs vol. 35,12 (2021): 1289-1301. doi: https://doi.org/10.1007/s40263-021-00856-3
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Chiesa V, Dainese F, De Maria G, Didato G, Falcicchio G, Fanella M, Ferlazzo E, Fisco G, Gangitano M, Giallonardo AT, Giorgi FS, La Neve A, Mecarelli O, Montalenti E, Piazza F, Pulitano P, Quarato PP, Ranzato F, Rosati E, Tassi L, Di Bonaventura C. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST). CNS Drugs. 2021 Dec;35(12):1289-1301. doi: 10.1007/s40263-021-00856-3. Epub 2021 Sep 02. PMID: 34476770.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 81 entries